The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will begin offering minimal/measurable residual disease (MRD) testing for select patients with Acute Myeloid Leukemia (AML) starting the week of April 11, 2022. Key points regarding this new testing are outlined in the memo below.